Table 2.
Clinical Parameters and Imagine Features of the Training Cohort and Validation Cohort.
| Parameters | Training Cohort (n = 243) | Validation Cohort (n = 122) | P-Value |
|---|---|---|---|
| VETC | |||
| Negative | 185 (76.1%) | 93 (76.2%) | .999 |
| Positive | 58 (23.9%) | 29 (23.8%) | |
| LMR | |||
| ≤7.75 | 229 (94.2%) | 116 (95.1%) | .928 |
| >7.75 | 14 (5.8%) | 6 (4.9%) | |
| PLR | |||
| ≤40 | 86 (35.4%) | 45 (36.9%) | .869 |
| >40 | 157 (64.6%) | 77 (63.1%) | |
| Neutrophil | |||
| ≤7 | 227 (93.4%) | 118 (96.7%) | .287 |
| >7 | 16 (6.6%) | 4 (3.3%) | |
| AAR | |||
| ≤.86 | 100 (41.2%) | 56 (45.9%) | .451 |
| >.86 | 143 (58.8%) | 66 (54.1%) | |
| ALRI | |||
| ≤29.75 | 179 (73.7%) | 87 (71.3%) | .725 |
| >29.75 | 64 (26.3%) | 35 (28.7%) | |
| ANRI | |||
| ≤12.43 | 158 (65%) | 76 (62.3%) | .692 |
| >12.43 | 85 (35% | 46 (37.7%) | |
| APRI | |||
| ≤.21 | 128 (52.7%) | 56 (45.9%) | .267 |
| >.21 | 115 (47.3%) | 66 (54.1%) | |
| BLRI | |||
| ≤21.73 | 127 (52.3%) | 56 (45.9%) | .3 |
| >21.73 | 116 (47.7%) | 66 (54.1%) | |
| SII | |||
| ≤545.6 | 175 (72%) | 94 (77%) | .366 |
| >545.6 | 68 (28%) | 28 (23%) | |
| AFP(ln) | 4.76 ± 3.36 | 4.64 ± 3.12 | .924 |
| Tumor diameter (ln) | 1.53 (1.13, 1.87) | 1.62 (1.13,2.03) | .21 |
VETC: Vessels that encapsulate tumor cluster; LMR: lymphocyte to monocyte ratio; PLR: platelet-lymphocyte ratio; AAR: AST to ALT ratio; ALRI: AST to lymphocyte ratio index; ANRI: AST to neutrophil ratio index; APRI: AST to platelet ratio index; BLRI: ALT to lymphocyte ratio index; SII: systemic immune-inflammation index.